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The focal adhesion kinase (FAK) and epidermal
growth factor receptor (EGFR) are protein-tyrosine ki-
nases that are overexpressed and activated in human
breast cancer. To determine the role of EGFR and FAK
survival signaling in breast cancer, EGFR was stably
overexpressed in BT474 breast cancer cells, and each
signaling pathway was specifically targeted for inhibi-
tion. FAK and EGFR constitutively co-immunoprecipi-
tated in EGFR-overexpressing BT474 cells. In low
EGFR-expressing BT474-pcDNA3 vector control cells,
inhibition of FAK by the FAK C-terminal domain caused
detachment and apoptosis via pathways involving acti-
vation of caspase-3 and -8, cleavage of poly(ADP-ribose)
polymerase, and caspase-3-dependent degradation of
AKT. This apoptosis could be rescued by the dominant-
negative Fas-associated death domain, indicating in-
volvement of the death receptor pathway. EGFR over-
expression did not inhibit detachment induced by the
FAK C-terminal domain, but did suppress apoptosis, ac-
tivating AKT and ERK1/2 survival pathways and inhib-
iting cleavage of FAK, caspase-3 and -8, and poly(ADP-
ribose) polymerase. Furthermore, this protective effect
of EGFR signaling was reversed by EGFR kinase inhibi-
tion with AG1478. In addition, inhibition of FAK and
EGFR in another breast cancer cell line (BT20) endog-
enously overexpressing these kinases also induced apo-
ptosis via the same mechanism as in the EGFR-overex-
pressing BT474 cells. The results of this study indicate
that dual inhibition of FAK and EGFR signaling path-
ways can cooperatively enhance apoptosis in breast
cancers.
The invasion and metastasis of cancer require a controlled
process of basement membrane degradation, cell motility, and
anchorage-independent cell survival. The process of metastasis
requires a disseminating cancer cell to survive an environment
that actively promotes apoptosis. Thus, for a cancer cell to
effectively metastasize, it must possess survival signals that
suppress apoptosis. One survival signal that has recently been
shown to modulate apoptotic signaling is the focal adhesion
kinase (FAK)1 (1–3). This non-receptor protein-tyrosine kinase
localizes to points of cell contact with the extracellular matrix,
the focal adhesions (4, 5).
FAK was originally isolated as a tyrosine-phosphorylated
125-kDa protein in v-Src-transformed chicken embryo fibro-
blasts (6, 7). FAK includes an N-terminal domain with a pri-
mary autophosphorylation site (Tyr397) that directly interacts
with the Src homology-2 domain (8); a central catalytic domain
with major sites of phosphorylation (Tyr576/Tyr577); and a
C-terminal domain with two proline-rich segments and a focal
adhesion targeting subdomain, which binds paxillin, talin, and
other proteins (4, 9). FAK activity is regulated by extracellular
matrix receptors and integrins and is involved in cellular pro-
cesses such as spreading, motility, proliferation, and survival
(4, 10). A non-catalytic domain of FAK, FAK-related nonkinase
(FRNK; p41/p43), is expressed in chicken embryo cells (11),
initiated from an alternative promoter and start site residing
within an intron (12). Ectopic expression of FRNK causes de-
phosphorylation of FAK at Tyr397 (13) and blocks FAK-medi-
ated fibroblast migration (14).
FAK was shown to be overexpressed compared with normal
tissue counterparts in many human tumors, including breast,
colon, and thyroid carcinomas (15–18). In human tumor cells,
inhibition of FAK expression with antisense oligonucleotides to
FAK or overexpression of the focal adhesion targeting subdo-
main leads to cell rounding, detachment, reduction of invasion,
and apoptosis (1, 19–22). Furthermore, FAK has been shown to
suppress both transformation-associated apoptosis (2) as well
as anoikis (detachment-induced apoptosis) of epithelial cells
(23), suggesting that one function of FAK is to promote survival
in cells subjected to apoptotic signals. Consistent with this
hypothesis, constitutively active forms of FAK prevent anoikis
and stimulate transformation of epithelial cells, resulting in
anchorage-independent growth and tumor formation in nude
mice (23). Further evidence for the anti-apoptotic role of FAK
was shown in the leukemic cell line HL-60, where FAK is
associated with activation of NF-B and inhibition of caspase-3
(24). Conversely, caspase-3 and -6 may promote apoptosis in
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part by cleaving FAK and generating a C-terminal FRNK-like
polypeptide (25).
Recently, FAK was shown to be associated with the epider-
mal growth factor receptor (EGFR), also known as ErbB-1 (26,
27). When epidermal growth factor (EGF) binds to 170-kDa
EGFR, receptor homo- and heterodimerization is promoted,
activating receptor tyrosine kinase activity (28) and down-
stream signaling (reviewed in Refs. 29–32). EGFR is overex-
pressed or activated by autocrine growth factors in many types
of tumors, including breast (33, 34), thyroid (35), ovarian (36),
colon (37), head and neck (38), and brain (38, 39). Furthermore,
EGFR overexpression has been linked to a poor prognosis in
breast cancer (32, 40) and may promote proliferation, migra-
tion, invasion, and cell survival as well as inhibition of apo-
ptosis (41–43). Recent reports have suggested that FAK serves
to integrate EGFR signals upon EGF induction, promoting
tumor cell motility and invasion (22, 27). However, another
report suggests that FAK and EGFR are constitutively associ-
ated (26). Thus, the relationship between EGFR signaling and
FAK expression and activity during progression from a nonin-
vasive to an invasive and metastatic tumor phenotype is un-
known, and their cooperation in preventing apoptosis has not
been mechanistically examined.
In this study, we examined the role of FAK and EGFR in
survival signaling in a human breast cancer cell line model
system of EGFR overexpression. We stably overexpressed
EGFR in a cell line that endogenously overexpresses FAK
(BT474-EGFR cells) to compare the effects of EGFR survival
signaling with the parental cell line without EGFR
(BT474-pcDNA3 cells). We have demonstrated that dual inhi-
bition of FAK and EGFR cooperatively caused apoptosis in
breast cancer cells. In breast cancer cells that stably overex-
pressed EGFR, there was a constitutive association between
FAK and EGFR. Furthermore, EGFR signaling suppressed
death receptor-mediated apoptosis induced by the FAK C-ter-
minal domain (FAK-CD). The mechanism included activation
of AKT and ERK signaling pathways as well as protection of
FAK from caspase degradation that was reversed by an EGFR
kinase inhibitor. Dual inhibition of FAK by FAK-CD and of
EGFR by AG1478 cooperatively enhanced apoptosis in human
breast cancer cell lines via inhibition of signaling that involved
both tumor necrosis factor receptor (TNFR) family-dependent
AKT and ERK1/2 pathways. This is the first report of the role
of FAK and EGFR in apoptosis showing that simultaneous
inhibition of FAK and EGFR can be critical in induction of
apoptosis in breast cancer cell lines.
EXPERIMENTAL PROCEDURES
Cells and Cell Culture—BT474 breast carcinoma cells, described by
Xu et al. (2), were maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 5 g/ml insulin, and 1 g/ml penicillin/
streptomycin. The clone of the BT474 cell line used in this study had low
expression of EGFR (Her-1) and Her-2. BT20 breast carcinoma cells,
which overexpress EGFR (44), were maintained in Eagle’s minimal
essential medium containing 10% fetal bovine serum. Cell lines were
incubated at 37 °C in a 5% CO2 humidified incubator. For EGF stimu-
lation (Western blotting and immunoprecipitation), cells were serum-
starved overnight in serum-free medium. In FAK-CD-induced apoptosis
experiments, EGF was added three times at 0, 6, and 20 or 22 h of
adenoviral infection. EGF (Calbiochem) was used at 10 ng/ml for 10 min
for EGF-dependent signaling experiments. For inhibition of EGF stim-
ulation, pretreatment with the EGFR kinase inhibitor AG1478 was
done at 5 M for 15 min. In FAK-CD-induced apoptosis experiments,
BT474 cells were incubated with 5 M AG1478 for 24 h, and BT20 cells
were incubated with AG1478 for 72 h at 5 M (added fresh every 24 h).
Antibodies and Reagents—Polyclonal antibodies to p125FAK (A17)
were obtained from Santa Cruz Biotechnology, and anti-phospho-
ERK1/2 antibodies were obtained from Promega. Anti-FAK monoclonal
(4.47) and anti-ERK1/2 polyclonal antibodies were from Upstate Bio-
technology, Inc. Anti-phospho-Ser AKT and anti-total AKT antibodies
were from Cell Signaling Technology Inc. Anti-EGFR monoclonal anti-
body, horseradish peroxidase-conjugated anti-phosphotyrosine anti-
body RC20, and anti-caspase-3 and anti-poly(ADP-ribose) polymerase
(PARP) monoclonal antibodies were from Transduction Laboratories.
Anti-caspase-8 monoclonal antibody was from Pharmingen. Anti-phos-
pho-Tyr397 FAK and anti-phospho-Tyr418 Src antibodies were from BIO-
SOURCE. Anti-vinculin, anti--tubulin, and anti--actin antibodies
were obtained from Sigma. Anti-hemagglutinin (HA) monoclonal anti-
body was from Roche Molecular Biochemicals. The tyrphostin AG1478,
an inhibitor of EGFR autophosphorylation, was obtained from Calbio-
chem. PD98059, an inhibitor of ERK1/2, was obtained from Upstate
Biotechnology, Inc. Caspase inhibitors were obtained from Calbiochem.
Adenoviral Infection—Recombinant adenoviruses carrying the lacZ
gene (Ad-lacZ) and the HA-tagged FAK-CD gene, coding amino acids
693–1052 of FAK (Ad-FAK-CD) and the dominant-negative FADD pro-
tein (Ad-FADD), were propagated by Dr. J. Samulski and the Gene
Therapy Center Virus Vector Core Facility of the University of North
Carolina and are described in Ref. 2. Cells were plated at 1.5  106 in
100-mm culture plates and, after 24 h of attachment, infected with
adenoviruses at the optimal concentration in 7 ml of medium with 10%
serum. The optimal viral concentration was determined by infection of
cells with different viral concentrations, and viral titer that produced
95% cell infectivity was used. The optimal viral titer was 500 focus-
forming units/cell (obtained from the Gene Therapy Center Virus Vec-
tor Core Facility), which produced 99% cell infectivity and no toxic
effects for Ad-lacZ transduction, checked by X-gal staining. The same
viral titer was used for Ad-FAK-CD infection, causing 90% of cell
infectivity, determined by HA immunostaining. For co-infection exper-
iments, Ad-FADD was used with FAK-CD at 333 viral particles/cell,
which was shown to produce high levels of FADD protein inside BT474
cells (2). For BT474 cells, caspase inhibitors (Ac-DEVD-CHO, caspase-3
inhibitor; and Ac-YVAD-CHO, interleukin-converting enzyme inhibi-
tor) were added at 50 M (2) for 1 h before adenoviral infection and were
present during incubation with adenoviruses for 23–24 h. For BT20
cells, the cell-permeable caspase-3 inhibitor DEVD-CHO (Calbiochem)
was added at 5 M for 1 h before infection and was present during
adenoviral incubation, added fresh every 24 h. The ERK1/2 inhibitor
PD98059 was added at 10 M for 15 min before adenoviral infection and
was present during incubation with adenoviruses for 24 h. Under these
conditions, PD98059 inhibited phosphorylation of ERK1/2 in Ad-FAK-
CD-infected BT474-EGFR cells (data not shown).
Staining with X-Gal—Cells were infected with Ad-lacZ as described
above. Briefly, 24 h after infection, cells were fixed for 10 min on ice
with 2% formaldehyde and 0.2% glutaraldehyde in 1 phosphate-buff-
ered saline (PBS). After washing twice with 1 PBS, cells were stained
for 1–3 h with 1 g/ml X-gal in X-gal buffer (5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, and 2 mM MgCl2 in 1 PBS). X-gal-positive (blue) cells were
counted for determining of infection efficiency.
Transfections—To make a stable BT474 cell line expressing EGFR,
cells were transfected with 10 g of pcDNA3 plasmid alone to create
BT474-pcDNA3 vector control cells or with 10 g of EGFR-pcDNA3
plasmid (kindly provided by Dr. David Lee) to create BT474-EGFR
cells. Transfections were accomplished with 20 l of LipofectAMINE
(Invitrogen) in a 100-mm dish following the manufacturer’s protocol.
Stable BT474-EGFR and BT474-pcDNA3 clones were obtained using
RPMI 1640 medium with the selective antibiotic Geneticin (500 M;
G418, Invitrogen). Expression of EGFR was checked by Western blot-
ting with anti-EGFR antibody, and a clone with maximal EGFR expres-
sion was used for the study.
Immunoprecipitation and Western Blotting—Cells were washed
twice with cold 1 PBS and lysed on ice for 30 min in buffer containing
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 5 mM EDTA, 50 mM NaF, 1 mM NaVO3, 10%
glycerol, and protease inhibitors (10 g/ml leupeptin, 10 g/ml phenyl-
methylsulfonyl fluoride, and 1 g/ml aprotinin). The lysates were
cleared by centrifugation at 10,000 rpm for 30 min at 4 °C. Protein
concentration was determined using a Bio-Rad kit. The cleared lysates
with equivalent amounts of protein were incubated with 5 l of primary
antibody for 1 h at 4 °C and with 25 l of protein A/G-agarose beads
(Oncogene Research Products Inc.). The precipitates were washed three
times with the lysis buffer and resuspended in 30 l of 2 Laemmli
buffer. For Western blotting, boiled samples were loaded on Ready
SDS-10% polyacrylamide gels (Bio-Rad). The phosphorylation status of
the proteins examined was detected with horseradish peroxidase-con-
jugated anti-phosphotyrosine antibody RC20 in Tris-buffered saline/
Tween buffer containing 1% bovine serum albumin. The blots were
stripped in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 100 mM -mercap-
toethanol at 60 °C for 30 min and reprobed with primary antibody to
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check equal loading of proteins. Immunoblots were developed with
Renaissance chemiluminescence reagent (PerkinElmer Life Sciences).
Immunostaining—Attached or detached suspended cells (collected
by centrifugation and spread evenly on the slide) were fixed in 4%
paraformaldehyde in 1 PBS for 10 min and permeabilized with 0.2%
Triton X-100 for 5 min on ice. Cells were blocked with 25% normal goat
serum in 1 PBS for 30 min, washed with 1 PBS, and incubated with
primary antibody diluted 1:200 in 25% goat serum in 1 PBS. Cells
were washed three times with 1 PBS, and a TRITC-conjugated sec-
ondary antibody (1:400 dilution in 25% goat serum) was applied to the
coverslip. After washing three times with 1 PBS, cells were incubated
with fluorescein isothiocyanate-BodipyFL-phallacidin (1:25 dilution in
25% goat serum; Molecular Probes, Inc.) for actin staining. For co-
immunostaining experiments, cells were incubated with another pri-
mary antibody diluted 1:100 in 25% goat serum in 1 PBS for 1 h. After
washing three times with 1 PBS, a fluorescein isothiocyanate-conju-
gated secondary antibody (1:100 dilution) was applied to the coverslip.
Apoptosis Assay—Detached cells were collected by centrifugation,
fixed in 3.7% formaldehyde in 1 PBS for 10 min, and stained with
Hoechst 33342 or spread evenly on a slide for TUNEL staining. In brief,
Hoechst 33342 in 1 PBS solution (1 g/ml) was added to the fixed cells
for 10 min, and cells were washed twice with 1 PBS and spread evenly
on the slide. TUNEL assay was done with an ApopTag fluorescein in
situ apoptosis detection kit (Intergen) according to the manufacturer’s
protocol. Simultaneous staining and quantification of apoptotic cells by
TUNEL assay and Hoechst methods produced very similar results. The
percent of apoptotic cells was calculated as the ratio of apoptotic cells to
total number of cells in three independent experiments in several fields
with a fluorescent microscope.
RESULTS
EGF-dependent Tyrosine Phosphorylation and Its Inhibition
by AG1478 in BT474-EGFR Cells—To test the relationship
between FAK and EGFR in breast cancer cell survival, we
created a model system of EGFR overexpression in a clone of
the BT474 breast carcinoma cell line (2), a cell line that ex-
presses high levels of p125FAK, but minimal levels of EGFR.
Parental BT474 cells were stably transfected with the
EGFR-pcDNA3 plasmid. These cells (called BT474-EGFR cells)
expressed high levels of EGFR compared with the pcDNA3
vector control cells (called BT474-pcDNA3 cells) (Fig. 1A). In
the BT474-EGFR cells, treatment with EGF at 10 ng/ml rap-
idly increased EGFR tyrosine phosphorylation, and this effect
was inhibited in the presence of the tyrphostin AG1478, an
EGFR kinase inhibitor (Fig. 1B). The BT474-EGFR cells had a
higher level of tyrosine-phosphorylated cellular proteins than
the vector control cells (Fig. 1C), and both BT474-pcDNA3 and
BT474-EGFR cells rapidly increased phosphorylation of
ERK1/2 at 10 min upon EGF stimulation and reversed this
effect upon AG1478 treatment (Fig. 1D). In addition, AKT
(Ser473) and FAK (phospho-Tyr397 and phospho-Tyr577) (data
not shown) were highly phosphorylated in the BT474-EGFR
cells.
FAK and EGFR Constitutively Associate in BT474-EGFR
Cells—To test whether FAK and EGFR were associated in the
BT474-EGFR cells, EGFR and FAK were immunoprecipitated
using anti-FAK monoclonal antibody (Fig. 2A, left panels). In
these experiments, anti-FAK antibodies precipitated EGFR
that was tyrosine-phosphorylated in the presence of EGF (Fig.
2A, upper left panel). Immunoprecipitation with anti-EGFR
antibodies also precipitated FAK (Fig. 2A, right panels). The
FAK and EGFR association was constitutive, as detected in the
presence and absence of EGF (Fig. 2A). Thus, FAK and EGFR
are physically associated in these breast cancer cells. Tyrosine
phosphorylation of total cellular FAK was not affected by the
EGFR inhibitor AG1478 (Fig. 2A, left panels), although a small
portion of phosphorylated FAK that was associated with EGFR
was inhibited by AG1478 (upper right panel). Dual immunoflu-
orescence assays in individual cells demonstrated that FAK
and EGFR were co-localized at focal adhesions in the BT474-
EGFR cells (Fig. 2B, left panels) and also in the BT20 cells,
which endogenously overexpress EGFR (right panels). These
results show that FAK and EGFR associate and co-localize at
the focal adhesions of these breast cancer cells.
Overexpression of EGFR Suppresses Apoptosis Induced by
FAK Down-regulation—Next, we tested whether overexpres-
sion of EGFR protects breast cancer cells from detachment and
apoptosis induced by FAK inhibition. In these experiments, we
down-regulated FAK function using Ad-FAK-CD in the BT474-
EGFR and BT474-pcDNA3 vector control cells. To inhibit FAK,
we used an adenoviral construct of the C-terminal domain
(Ad-FAK-CD) that has been shown to act as a dominant-nega-
tive for FAK function (2, 45, 46). In these experiments, we used
Ad-lacZ as a control at an equal multiplicity of infection. These
conditions resulted in 95% infectivity as assessed by X-gal
staining for Ad-lacZ (Fig. 3A) and by HA immunostaining for
HA epitope-tagged Ad-FAK-CD (Fig. 3B).
After 24 h of FAK-CD expression, there were similar levels of
loss of adhesion in the vector control cells (93  6%) and in the
EGFR-overexpressing cells (83  17%) (Fig. 4A) and only 0.5%
detachment by control Ad-lacZ at the same dose (data not
FIG. 1. EGF-dependent signaling and its inhibition by AG1478
in BT474-EGFR cells. A, Western blotting was performed with anti-
EGFR monoclonal antibody in the BT474-pcDNA3 vector control and
BT474-EGFR cells. Equal protein loading was analyzed by Western
blotting with anti--actin antibody. B, EGFR increases phosphorylation
after EGF stimulation and is inhibited in the presence of AG1478.
Immunoprecipitation (IP) was performed with anti-EGFR monoclonal
antibody, followed by the Western blotting (WB) with anti-phosphoty-
rosine antibody RC20. Cells were treated with EGF (10 ng/ml) for 10
min after overnight serum starvation. AG1478 (EGFR kinase inhibitor)
was used at 5 M for 15 min before EGF stimulation. C, shown is the
total phosphorylation of proteins. BT474 cells were serum-starved over-
night and induced by EGF (10 ng/ml) for 10 min with or without
AG1478 (5 M) pretreatment for 15 min. The human EGFR-overex-
pressing epidermoid carcinoma cell line A431 was used as a positive
control for induction of EGFR phosphorylation. Western blotting was
performed on total cell lysates with anti-phosphotyrosine antibody
RC20. Western blotting with anti--actin was performed on BT474
lysates to confirm equal protein loading. D, shown is ERK1/2 activation
in response to EGF treatment reversed by AG1478. ERK1/2 activation
was analyzed with anti-phospho-ERK1/2 antibody after EGF stimula-
tion for 10 min and with AG1478 pretreatment after overnight serum-
free medium starvation. Total ERK1/2 levels were determined with
anti-ERK1/2 polyclonal antibody. p-ERK1/2 indicates phosphorylated
active ERK1/2.
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shown). Furthermore, inhibition of EGFR kinase activity with
AG1478 did not enhance the loss of adhesion (Fig. 4A). These
results show that overexpression of EGFR does not augment
the ability of BT474 cells to resist loss of adhesion induced by
inhibition of FAK function.
In contrast, EGFR suppressed apoptosis induced by FAK
inhibition with Ad-FAK-CD. After 24 h of Ad-FAK-CD infec-
tion, detached BT474-EGFR cells had significantly reduced
levels of apoptosis (66%) compared with the BT474-pcDNA3
cells (97%) (Fig. 4B). Treatment of the BT474-EGFR cells with
EGF (10 ng/ml) did not enhance this resistance to apoptosis,
indicating that the maximal effect was already obtained by the
background autophosphorylation and signaling caused by
EGFR overexpression. However, inhibition of EGFR signaling
with AG1478 in the BT474-EGFR cells increased the level of
apoptosis to that in the BT474-pcDNA3 control cells (Fig. 4B).
In Hoechst-stained cells (Fig. 4C), apoptotic condensed nuclei
with fragmented chromatin in the BT474-EGFR cells were
maximal with both FAK and EGFR inhibition. In addition,
when FAK was inhibited by FAK-CD and ERK1/2 was inhib-
ited by PD98059 (ERK1/2 inhibitor) in the BT474-EGFR cells,
the level of apoptosis was increased to that in the
BT474-pcDNA3 vector controls (Fig. 4D), suggesting that
ERK1/2 enhances survival signaling in these breast cancer
cells. Taken together, these results demonstrate that EGFR
overexpression confers additional survival signals in the breast
cancer cells that suppress the apoptosis-inducing effect caused
by loss of FAK function.
FIG. 2. FAK constitutively associates with EGFR in BT74-
EGFR cells. A, BT474 cells were stimulated with EGFR as described in
the legend to Fig. 1. Left panels, immunoprecipitation (IP) was per-
formed with anti-FAK monoclonal antibody 4.47, and Western blotting
(WB) was done with anti-phosphotyrosine antibody. The membrane was
stripped, and Western blotting was performed with anti-FAK antibody
and then stripped again and reprobed with anti-EGFR antibody to show
that FAK coprecipitated with EGFR. Right panels, the same experi-
ment was performed with immunoprecipitation of EGFR, detecting
FAK and EGFR association. The experiment was done three times with
the same results. The images are composites from the same films/gels.
B, FAK and EGFR association and co-localization at focal adhesions
was detected by co-immunostaining. Immunostaining was performed
with mouse anti-FAK monoclonal primary antibody 4.47 and probing
with rhodamine-conjugated anti-mouse secondary antibody. After
washing, dual immunostaining was performed with anti-EGFR mono-
clonal antibody and probing with fluorescein isothiocyanate (FITC)-
conjugated anti-mouse secondary antibody. The merged images were
obtained with Adobe Photoshop Version 6.0.
FIG. 3. Adenovirus-mediated expression of FAK-CD and lacZ
in BT474 cells. BT474 cells were infected with Ad (Adeno)-lacZ and
Ad-FAK-CD as described under “Experimental Procedures.” In titration
experiments, the viral titer was detected with maximal cell infectivity.
At the optimal viral concentration (500 focus-forming units/cell),
100% of cells were X-gal-positive (blue) as determined by X-gal stain-
ing for Ad-lacZ infection (A), and HA-positive cells were determined by
immunostaining with anti-HA antibody for Ad-HA-tagged FAK-CD in-
fection after 24 h of infection (B). B: upper panel, detached cells were
stained with fluorescein isothiocyanate-BodipyFL-phallacidin, which
stains actin inside cells, for better cell visualization of cells under a
fluorescent microscope. Lower panel, HA-rhodamine immunostaining
showed that 100% of the cells expressed HA-tagged FAK-CD. lacZ-
positive cells were captured at 40 magnification, and HA-tagged FAK-
CD-expressing cells, which have a round morphology after 24 h, were
captured at 100 magnification under a fluorescent microscope.
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FIG. 4. BT474 cells overexpressing EGFR suppress apoptosis, but not cell detachment induced by FAK down-regulation. A, Ad
(Adeno)-FAK-CD infection stimulates cell detachment in BT474 cells. BT474-pcDNA3 and BT474-EGFR cells were infected with Ad-FAK-CD or
Ad-lacZ (see “Experimental Procedures”) at 500 focus-forming units/cell, resulting in 100% cell infectivity. After 24 h, Ad-FAK-CD-infected detached
cells were counted using a hemocytometer. Ad-lacZ-infected cells were resistant to detachment and were not apoptotic (data not shown). Four
independent experiments were done with the same results, and a representative experiment is shown. The mean percent  S.D. of detached cells is
shown from three independent cell counts using a hemocytometer. B, apoptosis induced by Ad-FAK-CD is inhibited by EGFR overexpression and
reversed by the EGFR kinase inhibitor AG1478. Detached BT474 cells that were infected with Ad-FAK-CD were fixed and analyzed for apoptosis.
Apoptosis was determined by Hoechst staining. Ad-lacZ-infected cells were not apoptotic (data not shown). Bars represent mean values  S.D. More
than 100 cells were counted in three independent fields for each experimental treatment in three independent experiments. C, Hoechst staining of
BT474 cells treated with Ad-FAK-CD. Apoptotic Ad-FAK-CD-infected cells with fragmented nuclei had bright Hoechst staining of condensed nuclear
chromatin. Ad-lacZ-infected cells did not undergo apoptosis and had unfragmented nuclei, as did control BT474 cells (data not shown). Left panels, cells
viewed for phase contrast; right panels, identical cells viewed for Hoechst-stained nuclei. Normal cells had faintly stained nuclei, whereas apoptotic
condensed nuclei stained brightly. D, the ERK1/2 inhibitor PD98059 increases Ad-FAK-CD-induced apoptosis in BT474-EGFR cells. BT474-EGFR cells
were pretreated with 10 M PD98059 for 15 min before Ad-FAK-CD treatment. PD98059 was present during adenoviral incubation for 24 h. After 24 h
of adenoviral infection, apoptosis was measured as described for B. The graph shows PD98059-increased apoptosis in BT474-EGFR cells. Bars
represent means  S.D. More than 100 cells were counted in three independent fields for each experimental treatment in three independent
experiments. Statistical significance was determined using Student’s t test. *, a significant difference from the pcDNA3 control (p  0.02); **, a
significant difference from the EGFR sample (p  0.040). Hoechst-stained nuclei are also shown.
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Inhibition of FAK and EGFR in BT474-EGFR Cells Down-
regulates Both ERK1/2 and TNFR Family-dependent AKT
Survival Pathways—Because EGFR appeared to function as a
survival signal to protect breast cancer cells from apoptosis
induced by FAK down-regulation, we investigated the down-
stream biochemical pathways for EGFR and FAK, beginning
with the MAPK pathways. After 24 h of infection with Ad-FAK-
CD, the BT474-EGFR cells demonstrated up-regulation of
phosphorylated ERK1/2 that could be inhibited by the EGFR
kinase inhibitor AG1478 (Fig. 5). This high level of ERK1/2
phosphorylation was not seen in the BT474-EGFR cells treated
with control Ad-lacZ or in the pcDNA3 vector control cells
treated with Ad-FAK-CD, showing that Ad-FAK-CD initiates
an EGFR-mediated stress response and survival signaling that
includes ERK1/2 phosphorylation.
We also examined the AKT (protein kinase B) pathway (47)
because FAK has been shown to act upstream of this serine/
threonine kinase, which has important survival signal func-
tions in tumor cells (48). AKT was constitutively expressed and
Ser473-phosphorylated in the BT474-EGFR cells as well as in
the BT474-pcDNA3 control cells treated with control Ad-lacZ
(Fig. 5). The BT474-pcDNA3 cells treated with Ad-FAK-CD
down-regulated AKT, as total AKT and Ser473-phosphorylated
AKT were not present in these cells (Fig. 5, third and fourth
panels, third lanes). In contrast to the BT474-pcDNA3 control
cells, the BT474-EGFR cells (independent of EGF ligand) ex-
pressed AKT and the active Ser473-phosphorylated form of AKT
in response to down-regulation of FAK (Fig. 5). However, when
EGFR kinase activity was inhibited by AG1478 in the BT474-
EGFR cells, there were undetectable levels of AKT protein
upon Western blotting, and AKT was completely dephospho-
rylated (Fig. 5). Based on these data, EGFR not only signals
through ERK1/2, but also has an effect on the ability of AKT to
resist down-regulation in response to FAK inhibition.
To further assess the relationship of EGFR overexpression
and FAK down-regulation to the ERK1/2 and AKT pathways in
BT474 cells, we inhibited TNFR family signaling in the BT474-
EGFR and BT474-pcDNA3 cells, based on our recent data that
the TNFR family regulates FAK-CD-induced apoptosis (2). To
analyze if these receptors are important in reduction of AKT
protein levels in apoptotic BT474-pcDNA3 cells infected with
Ad-FAK-CD, we blocked death receptor pathways by co-infec-
tion of cells with adenoviral dominant-negative FADD lacking
amino acids 1–79 of the death effector domain (Ad-FADD)
(49). Under these conditions, where the death complex was
inhibited, AKT protein levels were not reduced, and AKT was
Ser473-phosphorylated in the BT474-pcDNA3 and BT474-
EGFR cells (Fig. 5, last two lanes). The results demonstrate
that AKT down-regulation (reduction of protein levels) is me-
diated through a TNFR family pathway in the BT474-pcDNA3
cells infected with Ad-FAK-CD. In contrast, dominant-negative
FADD had no effect on ERK1/2 phosphorylation in the cells,
indicating the independence of the ERK1/2 survival pathway
from the TNFR family pathways (Fig. 5). These results show
that TNFR family signaling, which is involved in FAK-CD-
induced apoptosis, is also important in down-regulation/cleav-
age of AKT. Taken together, these biochemical results parallel
the cell biological results above, whereby inhibition of both
FAK and EGFR caused both the highest level of apoptosis as
well as inhibition of both the MAPK (ERK1/2) and TNFR
family-dependent AKT signaling pathways.
EGFR Overexpression Protects p125FAK and Caspase-3 and
-8 from Complete Degradation in Response to FAK Inhibition in
BT474 Cells Reversed by AG1478—To further examine the
effects of EGFR on resistance to apoptosis, we tested whether
overexpression of EGFR would protect endogenous p125FAK in
the breast cancer cells from degradation in response to Ad-
FAK-CD. Previous work from our group has shown that
p125FAK is degraded 24 h after Ad-FAK-CD infection in paren-
tal BT474 cells and that this effect is mediated through
caspase-8 and -3 (2). Similarly, in these studies, the p125FAK
protein was degraded in the BT474-pcDNA3 control cells upon
infection with Ad-FAK-CD (Fig. 5). However, in the BT474-
EGFR cells, EGFR overexpression protected p125FAK from
complete degradation by Ad-FAK-CD, as shown by the 125-kDa
FAK band that was present in the BT474-EGFR cells, but not
in the BT474-pcDNA3 cells (Fig. 5, third through fifth lanes).
Down-regulation of both FAK and EGFR did lead to complete
degradation of p125FAK in the BT474-EGFR cells, whereby
probing the Western blots with an antibody to the N terminus
of FAK detected only 85–90-kDa degradation products (Fig. 5,
sixth and seventh lanes). Co-infection of the BT474 cells with
Ad-FAK-CD and Ad-FADD blocked cleavage of FAK (Fig. 5).
In the BT474-pcDNA3 cells, treatment with Ad-FAK-CD
FIG. 5. EGFR-overexpressing BT474 cells infected with Ad-
FAK-CD activate ERK1/2 and AKT signaling pathways and par-
tially protect FAK from degradation. Ad-FADD blocked FAK
degradation and AKT down-regulation caused by Ad-FAK-CD.
BT474-pcDNA3 and BT474-EGFR cells were treated with either control
Ad-lacZ or Ad-FAK-CD with or without EGFR kinase inhibition by
AG1478 and analyzed for ERK1/2 and AKT activation and FAK degra-
dation. ERK1/2 activation was analyzed by Western blotting (WB) with
anti-phospho-ERK1/2 and anti-total ERK1/2 antibodies. ERK1/2 was
activated in BT474-EGFR cells infected with Ad-FAK-CD in the pres-
ence or absence of EGF and inhibited by AG1478 treatment. AKT status
was analyzed with anti-phospho-Ser473 AKT and anti-total AKT anti-
bodies. AKT was not detected in BT474-pcDNA3 cells infected with
Ad-FAK-CD, but was detected in control cells infected with Ad-lacZ.
BT474-EGFR cells expressed active serine-phosphorylated AKT and
total AKT after Ad-FAK-CD infection. Treatment with AG1478 in the
presence or absence of EGF caused down-regulation of AKT. Ad-
FADD protected AKT from down-regulation and FAK from complete
degradation. Western blotting with anti-HA antibody controlled for
HA-tagged FAK-CD protein levels in the samples. Equal protein load-
ing was controlled with anti--tubulin antibody. Each experiment was
performed five times with different adenoviral preparations with the
same results, and a representative experiment is shown.
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induced caspase-3 activation and PARP (caspase-3 substrate)
cleavage (Fig. 6A). Pretreatment of these cells with the Ac-
DEVD-CHO peptide (a caspase-3 family inhibitor) prior to in-
fection with Ad-FAK-CD blocked activation of caspase-3 and
cleavage of PARP and increased the levels of total AKT and
FAK (Fig. 6A), indicating that reduction of AKT and FAK
protein levels is the result of FAK and AKT cleavage by a
caspase-3 pathway in BT474 cells.
In contrast, overexpression of EGFR protected caspase-3 and
-8 from degradation caused by FAK down-regulation. In the
BT474-EGFR cells treated with Ad-FAK-CD, there was signif-
icant protection of caspase-3 from cleavage, with incomplete
PARP cleavage (Fig. 6B, fourth and fifth lanes). However, when
EGFR was inhibited under these conditions, the cleavage of
caspase-3 and PARP was restored to levels equivalent to those
in the BT474-pcDNA3 cells (Fig. 6B, third, sixth, and seventh
lanes). The upstream caspase-8 showed a similar effect,
whereby the BT474-EGFR cells did not activate caspase-8 in
response to FAK-CD, but in combination with EGFR inhibition,
cleaved the inactive proform and activated the enzyme (Fig.
6C). Co-infection of the BT474-pcDNA3 cells with Ad-FAK-CD
and Ad-FADD protected caspase-8 and -3 and PARP from
cleavage (Fig. 6).
Dual Inhibition of FAK and EGFR in BT20 Breast Cancer
Cells, Which Endogenously Overexpress EGFR, Enhances Apo-
ptosis, Down-regulating AKT and ERK1/2 Survival Path-
ways—In a final series of experiments, we tested whether
endogenous EGFR in a breast cancer cell line would have
similar survival signal effects as our model system of EGFR
overexpression in the BT474-EGFR cells. We used the BT20
cell line, which has been shown to express high levels of endog-
enous EGFR (44).
Similar to the BT474-EGFR cells, inhibition of FAK by Ad-
FAK-CD in BT20 breast cancer cells induced loss of adhesion,
although this effect was seen at later time points, 46–71 h after
adenoviral infection. The BT20 cells treated with Ad-FAK-CD
started to detach at 46 h, and 60% of the cells treated with
FAK-CD alone or with AG1478 in the absence or presence of
EGF detached by 71 h (Fig. 7A).
However, inhibition of FAK and EGFR enhanced the levels of
apoptosis in these cells (Fig. 7B) in a fashion similar to that
seen in the BT474-EGFR cells (Fig. 4B). At 46 h after infection,
the levels of apoptosis were slightly increased when cells were
FIG. 6. Caspase-3-dependent degradation of FAK and AKT in
BT474 cells. A, the caspase-3 inhibitor (Caspase-3 Inh.) Ac-DEVD-
CHO blocks Ad-FAK-CD-induced activation of caspase-3 and PARP
cleavage and degradation of FAK and AKT in BT474-pcDNA3 cells.
BT474-pcDNA3 cells were pretreated with the caspase-3 family inhib-
itor Ac-DEVD-CHO at 50 M (2) for 1 h before adenoviral infection.
After Ad-FAK-CD infection for 24 h, cells were collected and analyzed
for FAK and AKT protein levels as described in the legend to Fig. 5.
Caspase-3 activation was determined with anti-caspase-3 antibody,
specific to the inactive 32-kDa procaspase-3 protein. PARP (caspase-3
substrate) cleavage analysis was performed by Western blotting (WB)
with anti-PARP antibody, specific to uncleaved 116-kDa PARP. The
image is a composite from the same film (first and second lanes). B and
C, activation of caspase-3 and -8 and PARP in response to Ad-FAK-CD
is blocked in BT474-EGFR cells and reversed by inhibition of EGFR. B,
Ad-FAK-CD-induced activation of caspase-3 and PARP cleavage is
blocked in BT474-EGFR and Ad-FADD cells. Caspase-3 activation
was determined with anti-caspase-3 antibody. BT474-EGFR and Ad-
FADD cells suppressed caspase-3 activation. PARP cleavage analysis
was performed by Western blotting with anti-PARP antibody, specific to
uncleaved 116-kDa PARP, on the same lysates as in A. Loading was
controlled with anti--tubulin antibody. Each experiment was repeated
three times with two independent Ad-FAK-CD adenoviruses with the
same results, and a representative experiment is shown. C, activation
of caspase-8 cleavage in BT474 cells infected with Ad-FAK-CD is
blocked by EGFR and Ad-FADD expression. Caspase-8 activation was
determined with anti-caspase-8 antibody, specific to uncleaved inactive
55-kDa caspase-8. BT474-EGFR and Ad-FADD cells suppressed
caspase-8 activation. -Actin protein was used for normalization of
protein levels.
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treated with FAK-CD and AG1478 compared with cells that
had been treated with FAK-CD alone (7% versus 1.6%). How-
ever, at 71 h, this effect was more apparent, where the apo-
ptotic rate with FAK-CD alone was 10%, but addition of the
EGFR kinase inhibitor increased the rate to 33 and 43% (with-
out and with EGF, respectively) (Fig. 7B).
Next, we directly compared the biochemical effects of FAK
and EGFR inhibition in the BT474-EGFR and BT20 cells. As
shown by control Ad-lacZ infection, the levels of endogenous
EGFR and p125FAK expression as well as the levels of AKT
phosphorylation were higher in the BT20 cells (Fig. 8A, sixth
lane) than in the BT474-pcDNA3 cells (first lane) or the BT474-
EGFR cells (second lane). After 24 h of infection with Ad-FAK-
CD, the BT20 cells totally protected FAK from degradation
detected in the BT474-pcDNA3 cells (Fig. 8A). The ERK1/2
survival pathway was activated in the BT20 cells (as in the
BT474-EGFR cells), as ERK1/2 was highly phosphorylated in
BT20 cells infected with Ad-FAK-CD and dephosphorylated
upon treatment with AG1478. However, AKT remained highly
active and Ser473-phosphorylated in the BT20 cells after 24 h of
FAK-CD infection, as the BT20 cells had high levels of AKT
(Fig. 8A). At 72 h after FAK-CD expression and in the presence
of AG1478, the BT20 cells detached and had down-regulated
both ERK1/2 and AKT phosphorylation and also down-regu-
lated total p125FAK, caspase-3, and AKT proteins (Fig. 8B).
Next, we tested whether the degradation of FAK and AKT in
the BT20 cells is caspase-3-dependent, similar to the BT474
cells. To down-regulate FAK and AKT more efficiently in the
BT20 cells, we used the same dose of Ad-FAK-CD per cell, but
concentrated it 3.5-fold in the culture medium. Under these
conditions, FAK and AKT were completely down-regulated at
55 h (Fig. 8C). However, pretreatment of cells with the
caspase-3 subfamily inhibitor DEVD-CHO blocked degradation
of FAK and AKT (Fig. 8C), demonstrating that FAK and AKT
down-regulation in the AG1478- and Ad-FAK-CD-treated BT20
cells was caspase-3-dependent. These results mechanistically
support the increased levels of apoptosis seen upon Hoechst
staining in the detached cells treated with Ad-FAK-CD and
AG1478 and show that dual inhibition of EGFR and FAK
increased apoptosis in the BT20 cell line, inhibiting the same
survival signaling pathways as the BT474-EGFR cells.
DISCUSSION
This study demonstrates the cooperativity of both FAK and
EGFR signals in suppressing apoptosis in breast cancer cells.
Although there appears to be a physical association of these
tyrosine kinases, their individual survival signals appear also
in part to be in parallel. Thus, inhibition of both FAK and
EGFR signaling pathways led to significantly higher levels of
apoptosis than inhibition of either one alone. These results
were supported at a biochemical level, whereby the EGFR-
overexpressing cells had increased levels of both ERK1/2 and
AKT phosphorylation and did not demonstrate complete
p125FAK or caspase-3 or -8 degradation until both FAK and
EGFR signaling had been interrupted. Thus, this study is the
first to show the cooperative effect of FAK and EGFR inhibitors
in induction of apoptosis in human breast cancer cells. We
propose a model of survival signaling in breast cancer cells
whereby FAK and EGFR overexpression can promote survival
signals via an AKT-dependent mechanism as well as via an
ERK1/2 pathway (Fig. 9). Dual inhibition of FAK and EGFR led
to apoptosis via death receptor-mediated signaling.
Individually, both FAK and EGFR have been shown to be
overexpressed in human breast cancer specimens (15, 17, 18).
However, the relationship between these kinases and the sub-
sequent cellular effects in breast cancer remain unclear. It has
been shown that FAK and EGFR can associate when coex-
pressed in FAK/ fibroblasts in the presence of EGF (27),
suggesting that FAK can mediate a linkage between growth
factor receptors and integrins. Similarly, the association of
FAK and EGFR has been shown in A431 epidermoid cancer
cells (26) and A549 adenocarcinoma cells (22), both of which
express extraordinarily high levels of EGFR (50, 51). However,
these studies differed in whether FAK and EGFR constitu-
tively associate (26) or whether this association requires EGF
ligand (22). Our results support a constitutive association be-
tween FAK and EGFR in BT474 breast cancer cells stably
overexpressing EGFR, but it is unclear what effect this associ-
ation has on downstream signaling pathways.
The studies of FAK and EGFR in cancer cells have largely
focused on their effects on tumor cell motility. Inhibition of
FAK in A549 cells was shown to inhibit EGF-stimulated mo-
tility (22), providing further evidence that FAK can integrate
motility signals from EGF to EGFR. Other motility studies
suggest that FAK is dephosphorylated in response to EGF,
promoting tumor invasion and motility (26). In studies of hu-
man glioblastoma cells, inhibition of FAK function by exog-
enously expressing the focal adhesion targeting domain also
diminished EGFR-directed cell motility (19). We have exam-
ined motility of breast cancer cells in our system and found that
FIG. 7. BT20 breast cancer cells, which endogenously overex-
press EGFR, show detachment and increased apoptosis with
FAK and EGFR inhibition. A, detachment assay was done as de-
scribed for BT474 cells in the legend to Fig. 4A. BT20 cells started to
detach at 46 h after Ad (Adeno)-FAK-CD infection, with 60% cells
detached at 71 h. At 71 h, cells were equally detached in all treated
samples. Cells did not detach after Ad-lacZ infection (data not shown).
B, at 71 h, apoptosis was increased in BT20 cells by FAK and EGFR
inhibition, with and without EGF. Apoptosis was determined as de-
scribed in the legend to Fig. 4B. Two independent experiments were
done with the same results, and a representative experiment is shown.
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down-regulation of FAK rapidly diminished both random and
EGF-directed cell motility (data not shown), supporting the
hypothesis that FAK is involved in EGF-directed motility path-
ways. Thus, the model proposed by Hauck et al. (22) is consist-
ent with our findings in breast cancer cells. In their model,
interactions between FAK and EGFR and between FAK and
integrins concomitant with Src family activity via FAK phos-
phorylation at Tyr397 activate the downstream pathway that
promotes motility.
However, it appears that the effects of FAK overexpression
in breast cancer cells are not simply limited to motility and
invasion, but can cooperate with EGFR signaling to suppress
apoptosis and to enhance survival of breast cancer cells. Stud-
ies of FAK in primary breast cancer specimens have shown that
up-regulation of FAK expression is an early event in tumori-
genesis, occurring in ductal carcinoma in situ, before the tumor
has developed the capacity for invasion and metastasis (18).
These observations support the hypothesis that FAK functions
to promote survival during tumor cell proliferation before in-
vasion and migration have occurred. Furthermore, other stud-
ies in breast cancer cell lines suggest that FAK has two sepa-
rate functions in human tumor cells: one promoting adhesive
interactions between tumors and the matrix and the other
providing survival signals to resist apoptosis (2). Our results in
this study also support this hypothesis, whereby down-regula-
tion of FAK function had effects on apoptosis in EGFR-overex-
pressing breast cancer cells.
In this study, the biochemical mechanisms of apoptotic re-
sistance appeared to involve both the ERK and AKT pathways.
Overexpression of EGFR was associated with a robust phos-
phorylation of ERK1/2 in the BT474-EGFR cells, and this ap-
peared to augment the resistance to apoptosis induced by FAK
down-regulation. This is consistent with other studies impli-
cating the ERK pathways in apoptotic resistance, including
tumor necrosis factor--induced apoptosis in fibrosarcoma cells
(52) and stress-induced apoptosis in A431 cells (53). In the
latter study, Src-dependent phosphorylation of EGFR led to
ERK activation and the induction of survival signals in re-
sponse to UV irradiation (53). Other investigators have impli-
cated EGFR activation in keratinocyte survival by sustained
MEK/MAPK signaling activation (54). Intriguingly, EGFR has
been shown to transmit a survival signal to MAPK, even in the
absence of EGFR kinase activity (55), implicating other kinases
such as the Src family in this pathway. Nonetheless, the per-
sistent phosphorylation of ERK1/2 in our studies was also
associated with the inability of FAK inhibition to cause down-
regulation and dephosphorylation of AKT in EGFR-overex-
pressing cell lines. This suggests that EGFR also has a survival
signal function through this serine/threonine kinase. Further-
more, this effect appears to be dependent on EGFR kinase
activity, as AG1478 abrogated the protection of AKT. In fact,
several studies have shown that EGFR can signal directly to
AKT via phosphatidylinositol 3-kinase (42, 56–58). In a model
of oxidative stress-induced apoptosis, H2O2 activates AKT
through an EGFR/phosphatidylinositol 3-kinase-dependent
pathway (42). Similarly, activation of EGFR signaling in T47D
breast cancer cells and HEK293 cells protects these cells from
Fas-induced apoptosis via an AKT-dependent mechanism (56).
FIG. 8. Endogenous overexpression of EGFR protects FAK
from degradation and activates AKT and ERK1/2 survival path-
ways after FAK-CD expression reversed by the AG1478 inhibi-
tor. A, FAK and phospho-Ser473 AKT levels 24 h after Ad-FAK-CD
infection and AG1478 treatment. Western blotting with anti-EGFR,
anti-AKT, and anti-FAK antibodies was performed as described in the
legend to Fig. 5. The BT20 cell line did not degrade FAK at 24 h after
Ad-FAK-CD infection. BT20 cells had highly active AKT and ERK1/2
after FAK-CD infection. The HA-tagged FAK-CD expression level was
analyzed with anti-HA-antibody. B, FAK, phospho-Ser AKT, phospho-
ERK1/2, and caspase-3 levels 72 h after Ad-FAK-CD infection and
AG1478 treatment. BT20 cells had lower FAK, AKT (total and phospho-
Ser473), and phospho-ERK1/2 protein levels at 72 h of Ad-FAK-CD
infection in AG1478-treated samples. Phospho-ERK1/2 and ERK1/2
samples were run on a parallel gel with FAK and AKT samples, and a
composite image from the same film is shown for ERK samples. Protein
levels were analyzed as described for A with the same antibodies. C,
down-regulation of FAK and AKT in Ad-FAK-CD- and AG1478-treated
BT20 cells is caspase-3 family-dependent. BT20 cells were pretreated
first with the cell-permeable caspase-3 family inhibitor DEVD-CHO at
5 M for 1 h and then with AG1478 at 5 M and infected with Ad-FAK-
CD. Ad-FAK-CD was added at the same viral dose as in Fig. 8 (A and B),
but was 3.5-fold more concentrated (added in a 3.5-fold less volume of
medium for better infectivity and faster apoptotic response). Caspase-3
and AG1478 inhibitors were present during adenoviral incubation,
added fresh at the same doses every 24 h. Cells were collected at 55 h
after adenoviral infection. Western blotting (WB) was performed with
anti-caspase-3, anti-PARP, anti-FAK, and anti-AKT antibodies as de-
scribed in the legend to Fig. 6A. Equivalent amounts of total protein
from cell lysates were loaded on the gel.
FIG. 9. Model of FAK/EGFR-dependent apoptosis in breast
cancer cells with high levels of FAK and EGFR expression.
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These observations have recently been extended to TRAIL-
induced apoptosis, whereby signaling from EGFR to AKT pro-
tects HEK293 and MDA-MB-231 cells from apoptosis by inhib-
iting mitochondrial cytochrome c release (57). In our system,
the apoptosis induced by FAK down-regulation appeared to
function through similar receptor-mediated apoptotic path-
ways, consistent with our previous studies (2). In addition,
inhibition of the death complex with dominant-negative FADD
inhibited degradation of AKT, independent of ERK activation,
suggesting that the effects of FAK inhibition in these cells are
mediated through a TNFR family-mediated, AKT-dependent
pathway (Fig. 9). Furthermore, TNFR family FADD-dependent
AKT cleavage was recently reported in Madin-Darby canine
kidney epithelial cells (59). Ad-FAK-CD may induce death re-
ceptors by activating death domain-containing proteins such as
Fas, TNFR, and DR/TRAIL or by affecting adapter proteins
such as FADD, TRADD, and RIP. These events appeared to
activate the downstream caspase-8 and -3 cascade with cleav-
age of important survival proteins such as AKT and FAK (Fig.
9). In EGFR- and FAK-positive cells, binding of EGFR to FAK
may partially block FAK-CD-induced apoptosis, whereas
EGFR itself can signal directly to AKT and ERK1/2. Further-
more, EGFR survival signaling was kinase-dependent, as inhi-
bition of EGFR with AG1478 induced Ad-FAK-CD apoptosis
(Fig. 9). In addition, the magnitude of these effects was cell
type-specific, as breast cancer cells such as BT20 that express
high levels of FAK, EGFR, and AKT were more resistant to
inhibition of these pathways than BT474 cells, which express
lower levels of these survival proteins.
Our model of survival signaling in the BT474-EGFR and
BT20 breast cancer cells is that there are multiple cross-talk-
ing signaling pathways via ERK and AKT that augment the
resistance of tumor cells to the apoptosis-promoting effects of
tumor dissemination. The persistent signaling to AKT and
MAPK pathways contributes to the resistance to apoptosis in
these cells, which overexpress EGFR. From these studies, we
conclude that FAK and EGFR cooperatively suppress apoptosis
in breast cancer cells, suggesting that targeting both signaling
pathways will have an enhanced apoptotic effect in breast
cancers that overexpress these kinases.
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